FemHealth Ventures has closed its second fund at $65 million, more than doubling the size of its $35 million inaugural fund. The firm now manages $100 million across two funds.
The New Jersey-based venture capital firm invests in drugs, devices, diagnostics, and digital and AI-enabled technologies focused on women’s health. Fund I, launched in 2021, is a top-decile performer across DPI and IRR according to Carta and Pitchbook databases, according to the firm.
“We are thrilled to announce the successful close of Fund II, more than doubling the size of our inaugural fund,” said Maneesha Ghiya, Managing Partner of FemHealth Ventures. “This raise reflects growing recognition that women’s health innovation offers both substantial societal impact and compelling investment potential. We are grateful for the trust our limited partners continue to place in us.”
The fund received backing from existing limited partners as well as new investors.
FemHealth Ventures is known for developing the three-category framework defining women’s health as conditions that appear only in women, mostly in women, or differently in women.
“The next generation of transformative women’s health companies will be led by visionary founders, and we are honored to support them,” said Sara Crown Star, Venture Partner at FemHealth Ventures.
Fund II will continue the firm’s strategy of backing founders building solutions across the women’s health spectrum.
